Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.

Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q.

Oncol Lett. 2020 Apr;19(4):2629-2638. doi: 10.3892/ol.2020.11364. Epub 2020 Jan 31.

PMID:
32218813
2.

A Call to Action: Black/African American Women Surgeon Scientists, Where are They?

Berry C, Khabele D, Johnson-Mann C, Henry-Tillman R, Joseph KA, Turner P, Pugh C, Fayanju OM, Backhus L, Sweeting R, Newman EA, Oseni T, Hasson RM, White C, Cobb A, Johnston FM, Stallion A, Karpeh M, Nwariaku F, Rodriguez LM, Jordan AH.

Ann Surg. 2020 Mar 20. doi: 10.1097/SLA.0000000000003786. [Epub ahead of print]

PMID:
32209893
3.

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.

Petersen S, Wilson AJ, Hirst J, Roby KF, Fadare O, Crispens MA, Beeghly-Fadiel A, Khabele D.

Gynecol Oncol. 2020 Feb 7. pii: S0090-8258(20)30091-3. doi: 10.1016/j.ygyno.2020.01.038. [Epub ahead of print]

4.

Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.

Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ.

ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.

5.

Human papillomavirus vaccination completion rates among gynecological providers: an institutional retrospective review.

Elsamadicy EA, Schneiter MK, Hull PC, Khabele D.

Hum Vaccin Immunother. 2019;15(7-8):1851-1855. doi: 10.1080/21645515.2019.1619405. Epub 2019 Jun 11.

6.

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy.

Gupta V, Yull F, Khabele D.

Cancers (Basel). 2018 Sep 29;10(10). pii: E366. doi: 10.3390/cancers10100366. Review.

7.

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer.

Jewell A, McMahon M, Khabele D.

Cancers (Basel). 2018 Sep 1;10(9). pii: E296. doi: 10.3390/cancers10090296. Review.

8.

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.

Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.

9.

Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.

Beeghly-Fadiel A, Wilson AJ, Keene S, El Ramahi M, Xu S, Marnett LJ, Fadare O, Crispens MA, Khabele D.

J Ovarian Res. 2018 Feb 27;11(1):17. doi: 10.1186/s13048-018-0389-9.

10.

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.

Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.

Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.

11.

Cervical Cancer Screening and Follow-Up Procedures in Women Age <21 Years Following New Screening Guidelines.

Foxx AM, Zhu Y, Mitchel E, Nikpay S, Khabele D, Griffin MR.

J Adolesc Health. 2018 Feb;62(2):170-175. doi: 10.1016/j.jadohealth.2017.08.027. Epub 2017 Nov 22.

12.

Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-κB in Human Serous Ovarian Epithelial Tumors.

Choi H, Ignacio RMC, Lee ES, Wilson AJ, Khabele D, Son DS.

Immune Netw. 2017 Apr;17(2):121-127. doi: 10.4110/in.2017.17.2.121. Epub 2017 Apr 20.

13.

Blood type, ABO genetic variants, and ovarian cancer survival.

Cozzi GD, Levinson RT, Toole H, Snyder MR, Deng A, Crispens MA, Khabele D, Beeghly-Fadiel A.

PLoS One. 2017 Apr 27;12(4):e0175119. doi: 10.1371/journal.pone.0175119. eCollection 2017. Erratum in: PLoS One. 2017 May 30;12 (5):e0178965.

14.

Pragmatic trial of an intervention to increase human papillomavirus vaccination in safety-net clinics.

Sanderson M, Canedo JR, Khabele D, Fadden MK, Harris C, Beard K, Burress M, Pinkerton H, Jackson C, Mayo-Gamble T, Hargreaves MK, Hull PC.

BMC Public Health. 2017 Feb 2;17(1):158. doi: 10.1186/s12889-017-4094-1.

15.

Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.

Cozzi GD, Samuel JM, Fromal JT, Keene S, Crispens MA, Khabele D, Beeghly-Fadiel A.

BMC Cancer. 2016 Aug 8;16:612. doi: 10.1186/s12885-016-2660-z.

16.

Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.

Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D.

Gynecol Oncol. 2016 Oct;143(1):143-151. doi: 10.1016/j.ygyno.2016.07.088. Epub 2016 Jul 19.

17.

Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy.

Jiang X, Li H, Zhao P, Xie J, Khabele D, Xu J, Gore JC.

Neoplasia. 2016 Jun;18(6):387-97. doi: 10.1016/j.neo.2016.04.006.

18.

Incidental placenta increta at the time of prophylactic hysterectomy for Lynch syndrome: Insights into individualized decision-making and surgical timing.

Nielsen TA, David SN, Desouki MM, Crispens MA, Khabele D.

Gynecol Oncol Rep. 2015 Sep 25;14:20-2. doi: 10.1016/j.gore.2015.09.003. eCollection 2015 Nov.

19.

Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.

Wilson AJ, Saskowski J, Barham W, Khabele D, Yull F.

Mol Cancer. 2015 Nov 9;14:192. doi: 10.1186/s12943-015-0463-5.

20.

Results of a Health Education Message Intervention on HPV Knowledge and Receipt of Follow-up Care among Latinas Infected with High-risk Human Papillomavirus.

Sanderson M, Khabele D, Brown CL, Harbi K, Alexander LR, Coker AL, Fernandez ME, Brandt HM, Fadden MK, Hull PC.

J Health Care Poor Underserved. 2015 Nov;26(4):1440-55. doi: 10.1353/hpu.2015.0131.

Supplemental Content

Loading ...
Support Center